Novartis Posts Solid Quarter as New Drugs Struggle
Novartis reported third-quarter sales slightly above consensus, while core operating profit clearly beat forecasts. Vontobel's Stefan Schneider said recently launched products underperformed.
Story updates
01:40:14 PM UTC
SquawkNews
Novartis investors' attention will shift to an update on its midterm outlook next month, when the Swiss drugmaker could raise its peak-sales estimates for key drugs, Bank of America analysts say. The company reported third-quarter results, with core earnings per share beating consensus expectations…